The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1435
February 3, 2014
View Complete Issue         Table of Contents 2019 
Perampanel (Fycompa) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Perampanel (Fycompa) for Epilepsy
February 3, 2014 (Issue: 1435)
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Perampanel (Fycompa) for Epilepsy
Article code: 1435a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.